JPMorgan Chase & Co. downgraded shares of Lexicon Pharmaceuticals (NASDAQ:LXRX) from a neutral rating to an underweight rating in a report issued on Wednesday, MarketBeat Ratings reports. They currently have $10.00 price objective on the biopharmaceutical company’s stock, down from their prior price objective of $15.00.
Other equities analysts have also recently issued reports about the stock. BidaskClub upgraded shares of Lexicon Pharmaceuticals from a sell rating to a hold rating in a report on Tuesday, January 30th. Zacks Investment Research upgraded shares of Lexicon Pharmaceuticals from a sell rating to a hold rating in a report on Tuesday, November 14th. Wedbush restated an outperform rating and set a $38.00 price target on shares of Lexicon Pharmaceuticals in a report on Thursday, November 30th. Finally, ValuEngine cut shares of Lexicon Pharmaceuticals from a sell rating to a strong sell rating in a report on Friday, February 2nd. Three equities research analysts have rated the stock with a sell rating, two have assigned a hold rating and four have given a buy rating to the company’s stock. The company presently has a consensus rating of Hold and a consensus target price of $24.80.
Lexicon Pharmaceuticals (LXRX) opened at $7.86 on Wednesday. The company has a debt-to-equity ratio of 1.09, a quick ratio of 1.65 and a current ratio of 1.66. Lexicon Pharmaceuticals has a fifty-two week low of $7.80 and a fifty-two week high of $18.00.
COPYRIGHT VIOLATION NOTICE: “Lexicon Pharmaceuticals (LXRX) Downgraded by JPMorgan Chase & Co.” was first reported by Week Herald and is the property of of Week Herald. If you are reading this piece on another website, it was stolen and reposted in violation of U.S. & international copyright and trademark law. The correct version of this piece can be read at https://weekherald.com/2018/02/17/lexicon-pharmaceuticals-lxrx-downgraded-by-jpmorgan-chase-co.html.
About Lexicon Pharmaceuticals
Lexicon Pharmaceuticals, Inc is a biopharmaceutical company. The Company focuses on the development and commercialization of breakthrough treatments for human disease. Its drug programs include XERMELO (telotristat ethyl), sotagliflozin, LX2761 and LX9211. It also has a number of additional compounds into various stages of clinical and preclinical development.
Receive News & Ratings for Lexicon Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Lexicon Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.